For more than ten years there has been an ongoing debate as to whether anaesthesia causes a decline in cognitive function 1 . It is not uncommon for patients' relatives to report that: "Uncle Joe was never the same again after the anaesthetic" (the potential effects of the concomitant illness, surgery, and hospital stay are almost always ignored as possible causes). These ideas were further driven by animal studies which showed extensive neuronal apoptosis occurring with pretty much all inhalational and intravenous general anaesthetic drugs-except xenon and dexmedetomidine 2 . Volatile general anaesthetic agents are unusual in that they are not potent drugs (their effective concentrations are typically in the hundreds of µM range), they bind promiscuously to at least 10% of the proteins in the body, and clinically it is commonly perceived that patients don't wake up as smoothly as when propofol is used for hypnosis. Therefore Konishi and coworkers did a subanalysis of previously collected patient data, to see if the use of propofol as a hypnotic was associated with fewer long-term cognitive difficulties than when sevoflurane was the primary hypnotic 3 . They studied hip surgery patients in whom the general anaesthesia/sedation was given on top of a spinal anaesthetic. Presumably the spinal anaesthesia removed any neurally-mediated surgical noxious stimuli, but did not entirely remove the other inflammatory and endocrine responses to the trauma of surgery. The treatment allocation was not randomised, so that there exists the possibility that the anaesthetists' choice of treatment allocation may be biased one way or the other. Perhaps the anaesthetists would preferentially give propofol to agitated patients in whom they anticipated more problems on emergence? This does not seem to be the case, as the two groups looked to be wellmatched by the obvious clinical confounders.
The measurement of postoperative cognitive dysfunction is not simple, and has been the subject of some debate. Any index has to allow for: varying and complex pre-existing cognitive trajectories; learning (and boredom) effects when running multiple tests; and the whole experience of the social disruption that accompanies being hospitalised. The authors used a dichotomous outcome measure of postoperative cognitive dysfunction (POCD) derived from a series of ordinal scales. Each scale tests quite a different aspect of cognition (e.g. short-term memory, frontal lobe function etc). To take into account the variation in cognitive trajectories, they used the (encouragingly named) 'reliable change index' as a statistical measure of deviation from previous levels of function. This statistic was originally developed as a simple but sensitive measure of clinically significant individual responses to psychotherapy 4 , and has since become widely used by researchers in the field. Essentially it is a count of the outliers-i.e. the number of patients who have deteriorated such as to go beyond the confidence limits of the control population. One of the criticisms of the method is that some patients might actually improve with (propofol) anaesthesia and surgery, but are not reported. Also the fact that 2.6% of the patients were outside the confidence intervals at 12 months seems to suggest that there were no long-term adverse cognitive effects-as we would expect 2.5% of any normally distributed population to lie >1.96 standard deviations from the mean.
The conclusion of the study was that, on average, there was no significant difference in incidence of POCD between the patients receiving propofol and those receiving sevoflurane; and that POCD was not associated with increasing depth of anaesthesia (as estimated by the bispectral index). As reported in the discussion section of the paper, these results seem to be congruent with most other studies, which show little difference in average outcome. We could conclude that hypnotic drugs are mostly harmless, their possible adverse effects are transient, and there is no large difference between those patients who received sevoflurane and those who got propofol. From these results it would be hard to justify doing a large expensive intervention trial that the authors suggest.
However, the problem with existing research methodology is that we extrapolate from the (correct) statement: "use of sevoflurane versus propofol does not influence the incidence of POCD on average" to the (logically inconsistent) statement: "therefore sevoflurane does not harm ANYONE-even Uncle Joe". This conundrum is not solved by bigger trials, but by better understanding of the basic science underlying the causal processes necessary for the development of POCD.
